Inc. , (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Matt Wiley ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback